Envoy Medical, Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Envoy Medical announced its investigational Acclaim cochlear implant trial surpassed the six-month follow-up visit for all 56 patients and submitted the second of four planned PMA modules to the FDA post-quarter end. First 10 participants showed 12-month CNC word recognition improvement from 15.2% baseline to 53.2%, a 38 percentage-point gain. Company reported Q3 2026 net loss of $5.2M ($0.50/share) on $66K revenue, with cash of $14.6M and total assets of $19.2M as of September 30, 2026.
Why this rating
Major clinical progress on core product nearing FDA approval; six-month milestone achievement and PMA module submission are material regulatory milestones. Clinical efficacy data (38pp improvement) strongly supports approval path. Event is highly significant relative to $12.7M market cap but execution risks remain.
Tradability signal
NO TRADE
No trade: price $0.03 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $0.03 | +10 min · unknown $0.03 ▲ 0.00% | +30 min · unknown $0.03 ▲ 0.00% | +1 hr · unknown $0.03 ▲ 0.00% | +4 hrs · unknown $0.03 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.